Arcus Biosciences, Inc. (RCUS)
Automate Your Wheel Strategy on RCUS
With Tiblio's Option Bot, you can configure your own wheel strategy including RCUS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RCUS
- Rev/Share 1.4329
- Book/Share 5.3963
- PB 1.6548
- Debt/Equity 0.113
- CurrentRatio 5.3698
- ROIC -0.4479
- MktCap 945553050.0
- FreeCF/Share -3.0793
- PFCF -3.1206
- PE -2.2473
- Debt/Assets 0.0519
- DivYield 0
- ROE -0.7058
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | RCUS | H.C. Wainwright | Neutral | Buy | $18 | $24 | Feb. 26, 2025 |
| Initiation | RCUS | H.C. Wainwright | -- | Neutral | -- | $20 | Oct. 21, 2024 |
| Initiation | RCUS | Wells Fargo | -- | Overweight | -- | $29 | Oct. 8, 2024 |
News
Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Arcus Biosciences, Inc. (NYSE:RCUS ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Pia Eaves - VP, IR Terry Rosen - CEO Richard Markus - CMO Jennifer Jarrett - COO Bob Goeltz - CFO Juan Jaen - President Conference Call Participants Peter Lawson - Barclays Daina Graybosch - Leerink Partners Yigal Nochomovitz - Citigroup Umer Raffat - Evercore Eva Fortea - Wells Fargo Emily Bodnar - HC Wainwright Operator Hello, everyone. And welcome to Arcus Biosciences First Quarter 2025 Earnings and Financial Results Call.
Read More
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $0.05 per share a year ago.
Read More
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Published: February 26, 2025 by: Business Wire
Sentiment: Neutral
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Healthcare Conference 2025 Date: Wednesday, March 12th, 2025 Location: Miami Beach, FL Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Barclays 27th.
Read More
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to loss of $1.08 per share a year ago.
Read More
Arcus Biosciences Announces New Employment Inducement Grants
Published: February 24, 2025 by: Business Wire
Sentiment: Neutral
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 5,550 shares of the Company's common stock at an exercise price per share of $11.07, which was the closing price on February 21, 2025, and.
Read More
Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering
Published: February 18, 2025 by: Business Wire
Sentiment: Neutral
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that Gilead's time-limited exclusive option rights to casdatifan have expired. In addition, Arcus has announced the pricing of a $150 million common stock offering, which is subject to customary closing conditions and includes participation from new and existing.
Read More
Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock
Published: February 18, 2025 by: Business Wire
Sentiment: Neutral
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced the pricing of an underwritten offering of 13,636,364 shares of its common stock at an offering price of $11.00 per share, for total gross proceeds of approximately $150 million, before deducting underwriting discounts and commissions and offering expenses payable.
Read More
Arcus Biosciences Announces New Employment Inducement Grants
Published: February 11, 2025 by: Business Wire
Sentiment: Neutral
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Richard Markus, M.D., Ph.D., the Compensation Committee of the Company's Board of Directors granted Dr. Markus an option to purchase 305,328 shares of the Company's common stock.
Read More
About Arcus Biosciences, Inc. (RCUS)
- IPO Date 2018-03-15
- Website https://www.arcusbio.com
- Industry Biotechnology
- CEO Dr. Terry J. Rosen Ph.D.
- Employees 627